79 results about "Cell tumor" patented technology

The present invention refers to a composition based on monoterpenes with chemopreventive and chemotherapeutic effects in malignant neoplasias of humans and animals containing from 0,03% to 30% of monoterpenes and 99,97% of solvents. Another objective of the present invention is an application of monoterpenes in inhibition of cell growth and metastasis control of primary tumors being applied in vitro and in vivo gliomas cell lines C6 and U 87 and A172. Further another objective of the present invention refers to a specific methods for applying the composition with chemopreventive and chemotherapeutic effects in humans and animals showing malignant neoplasias by inhalation and nebulization treatment, oral and intratumoral, followed or not by radiotherapy with dilutions from 0,03% to 30% of the monoterpene perillyl or its derived metabolites diluted in the solvents specified by the usual techniques.

Methods and compositions are provided for detecting circulating tumor cells and assessing said cells for alterations in tumor-diathesis associated molecules.

Compositions for use in characterization, diagnosis, prognosis, and therapy of cancer cells are provided. The compositions comprise peptides and variants thereof which were isolated based on their ability to selectively bind glioma cells.

Genes that are differentially expressed in subtypes of renal cell carcinomas are disclosed as are their polypeptide products. This information is utilized to produce nucleic acid and antibody probes and sets of such probes that are specific for these genes and their products. Methods employing these probes, including hybridization and immunological methods, are used to determine the subtype of a renal cell tumor sample from a subject based on the differential expression of such genes that is characteristic of the cancer subtype.

The invention provides a CD7-CAR-T cell as well as preparation and application thereof. Particularly, the invention provides a chimeric antigen receptor (CAR), and an antigen binding domain of the CARcomprises one or more CD7 nanobodies. The invention further provides a CAR-T cell containing the CAR, and endogenous CD7 expression of the CAR-T cell is blocked. The CAR-T cell of the invention can be applied to treatment of T cell tumor.

The invention relates to a polypeptide with tumor-targeting performance and a preparation method. The structure of the aminophenol sequence of the polypeptide is CASPSGALRSC or CFPVPGHDLVC or CFSVPGHDIVC or CTPMSLSLSEC or CYTYPLGWHIC. The pC89 phage peptide library expressing protein polypeptides with different sequences of 108 and human breast cancer cell lines MDA-MB-231 are repetitively cocultured for a few times; filtration can penetrate cell membrane to enter into the phages expressing specific polypeptide in cytolymph and / or karyon, and phages are amplified in vitro in order to carry out DNA sequencing and deduce an exogenous amino acid sequence inserted in the phages; the filtered specific polypeptide phages, other human tumor cells and normal cells are cocultured in vitro, and the tumor cell specificity of the polypeptide phages is tested; according to the testing results of polypeptide sequence and cell specificity, the polypeptide with tumor targeting is artifically synthesized. The invention as a specificity carrier of the mammary cancer-targeting genetic therapy has potential clinic application value. The invention also provides a strong technical support for the filtration of affinity specificity polypeptide of other types of malignant tumor cell strains. Moreover, the polypeptide only contains nine to eleven amino acid residues, so the polypeptide can be easily synthesized, the change of spacial position is relatively less, the quality control of the polypeptide is easy, and use is convenient.

The invention provides a CD7 chimeric antigen receptor modified NK-92MI cell and an application thereof. Particularly, the invention provides an engineered NK cell that expresses a chimeric antigen receptor CAR, the antigen binding domain of which contains a nanoantibody VHH sequence targeting CD7. The NK cell can effectively kill tumor cells, especially T cell tumors, and has very good treatmenteffect on T cell leukemia (such as T-ALL).

A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject.

The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and / or conditions in which the PTP1B enzyme is a factor. Such diseases and / or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.

The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media / culture conditions, these cells can be induced to differentiate.The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.

Development of a physiologically relevant 3D model system for cancer research and drug development represents quite a challenge. We have adopted a 3D culture system based on a transglutaminase-crosslinked gelatin gel (Col-Tgel) to mimic tumor 3D microenvironment. The system has several unique advantages over other alternatives which include cell-matrix interaction sites provided by collagen derived peptides, a 3D construct suitable for reproducing the solid tumor microenvironment including multicellular tumor spheroids and metabolic gradients. In addition the controllable gel stiffness provides a wide range of mechanical restrictions; and compatibility with imaging based screening due to its transparent properties. In addition the Col-Tgel provides a cure-in-situ delivery vehicle for tumor xenograft formation in animals with a high take rate. Overall, this unique 3D system could provide a platform to accurately mimic in vivo situations to study tumor formation and progression both in vitro and in vivo, as well as for screening antineoplastic drugs and assessing the occurrence of drug resistance related to cancer cell stress.

A dendric cell tumor vaccine carrying withered heat shock tumor cells for preparing antineoplastic medicine and decreasing immune escape is prepared through treating tumor cells by heat shock method, inducing the wither of tumor cells, preparing dendric cells, and carrying the withered heat shock tumor cells.

The present invention provides multivalent vaccines for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom vaccines, including multivalent vaccines for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom vaccines.

The invention relates to a tumor targeting polypeptide and a preparation method thereof. The amino acid sequential structure of the polypeptide of the invention is CFPVPGHDLVC. The preparation method comprises the following steps: co-culturing a pC89 phage peptide library for expressing 108 protein polypeptides with different sequences and human breast cancer cell strain MDA-MB-231 repeatedly for many times; screening phages which express specific polypeptides and can penetrate a cell membrane and enter cytoplasm and / or nucleus, amplifying the phages in vitro and carrying out DNA sequencing, and deducing exogenous amino acid sequences inserted on the phages; co-culturing the screened specific polypeptide phages, other human tumor cells and normal cells in vitro, and detecting the specificity of cell tumor of the polypeptide phages; and according to the polypeptide sequences and the detecting result of the cell specificity, artificially synthesizing the tumor targeting polypeptide. The invention has potential clinical application values for specific vectors of breast cancer targeting gene therapy, and also provides powerful technical support for screening polypeptides with affinity and specificity of other types of malignant tumor cell strains in the future. In addition, the polypeptide of the invention contains only 9-11 amino acid residues, can be synthesized easily, and has relatively small spatial position change, easy quality control of the polypeptide and convenient use.

The present invention relates to an indole derivative and uses of the indole derivative in preparation of anti-cancer drugs for tumor inhibition, wherein a cyano indole compound and a boric acid compound can be subjected to one-step synthesis in the presence of a catalyst, a ligand and an additive so as to obtain the derivative. According to the present invention, the derivative has the excellent anti-cancer activity, and results of the activity test show that the derivative provides good tumor cell growth inhibition effects on human gastric cancer cell line (SGC-7901), human lung cancer cell line (H446) and human gastric cancer cell line (HGC-27), such that the derivative can be adopted as the anti-tumor drug in the medicine field and has good medical research prospects and industrial application values.

The recipe for the externally applied Chinese medicine for eliminating verruca piana consists of java brucea fruit, flavescent sophora root, black plum, abave grass, broom cypress fruit, dittany bark and safflower. All the medicine materials are extracted with organic alcohol to obtain mild medicine liquid. The medicine liquid can suppress the replication of virus inside verruca and eliminate the proliferation of epidermal cell tumor owing to its functions of softening dry feces and dissipating mass and promoting blood circulation to disperse blood clots, and has no injury to health skin. It can eliminate verruca piana effectively including disease focus in later stage.

The invention discloses medical devices and particular discloses an oral type cell tumor collector. The oral type cell tumor collector comprises a collector outer housing and a single valve and is characterized in that the a collector inner housing is arranged in the collector, the collector outer housing is provided with a helical cell collection groove connected to a cell collection tube, one end of the cell collection tube is connected to a collector outer tank, a collector inner tank is arranged in the collector outer groove, both ends of the collector inner groove are provided with an vent tube, the single valve is arranged in the middle portion of the vent tube, and one end of the vent tube is connected to a vent tube opening. The oral type cell tumor collector has the advantages of being simple in structure, easy to use, low in cost, capable of collecting tumor cells easily without harm to a patient, simple in examination process, capable of causing no pain to the patient in the examination process, accurate in collection result and capable of bringing great convenience to doctors and patients.

The invention provides a construction method of an immune cell tumor killing capacity detection model. The construction method comprises the following steps: (1) 24 after egg membranes of embryos of zebrafish fertilized for 24-96 hours are removed, injecting tumor cells labeled by a first living cell staining agent into zebrafish bodies, then executing culturing in culture water containing a melanin inhibitor, and screening out the zebrafish with the tail parts labeled by the first living cell staining agent; (2) after the collected zebrafish is anesthetized, the zebrafish is divided into an immune cell injection group and a control group, injecting immune cells labeled by a second living cell staining agent into the immune cell injection group in a microinjection mode, injecting a carriersolution into the control group, and then putting the zebrafish in the culture water containing the melanin inhibitor for continuous culture. Short period, time saving, labor saving and low modelingcost are achieved by adopting the construction method, and a constructed detection model can accurately and objectively evaluate the effect of tumor immunotherapy. The invention also provides a detection model prepared based on the method and application thereof.

Disclosed are a bacteriologically-modified whole-cell tumor vaccine and a method of making the same. The method includes: lysing bacteria at logarithmic growth phase to obtain a bacterial lysate; mixing the bacterial lysate with an excessive amino compound solution to aminate the bacterial lysate in the presence of EDC; mixing the aminated bacterial lysate with the tumor cells for a certain period of time to produce bacteriologically-modified tumor cells; and inactivating the bacteriologically-modified tumor cells to produce the bacteriologically-modified whole-cell tumor vaccine. The bacteriologically-modified whole-cell tumor vaccine has been demonstrated to have desirable therapeutic effect in tumor model mice.

The invention discloses a full-target antigen-presenting cell tumor vaccine as well as a preparation method and application thereof. The preparation method of the full-target antigen-presenting cell tumor vaccine comprises the following step of co-incubating quantum dot modified tumor cells and immature antigen-presenting cells, wherein the quantum dot modified tumor cells are obtained by connecting quantum dots and protein molecular chains of tumor cells through hydrogen bonds. After the quantum dot modified tumor cells and the immature antigen-presenting cells (APC) are co-incubated, the immature APC (such as MP or DC) can be converted from an immature state to a hyperactivity state, so that the uptake of the tumor antigen is enhanced, the MHC molecular expression is up-regulated on a large scale, and the antigen-presenting efficiency is improved; and meanwhile, the preparation process is simple, the cost is low, and an application prospect is excellent.

The invention relates to a preparation method of a folate-targeted 99mTc marked manganese-based chelate MR / SPECT dual-mode probe. The method comprises the following steps of: modifying G5 surface with a chelating reagent DOTA-NHS; connecting a targeting molecule to the G5 surface; marking the G5 with FI; chelating manganese ions in coordination with DOTA; converting G5 surface amino into acetyl through acetylation reaction; finally, marking the residual DOTA with radioactive nucleus 99mTc, thus obtaining the probe. The molecular imaging probe prepared by the invention realizes MR / SPECT dual-mode imaging at the cell level and the animal level; moreover, by mediation of FA, the probe prepared by the invention has remarkable targeting effect on a Hela cell tumor model of high-expression cancer cell strain of an FA receptor, and is expected to be used for realizing dual-mode targeting diagnosis on cancer.

The present invention relates to the fusion protein of heat shock protein and HPV16Z E6 / E7, the obtaining process and expression vector of the fusion protein, host with transformed expression vector, and the application of the fusion protein in medicine for preventing and treating HPV relative diseases. The fusion protein may be expressed in colibacillus in the form of inclusion body and further column renatured and chromatographically purified to reach purity over 95 %. It is used in inducing E6 and E7 specifying cellular immunity reaction in mouse body in the condition of no adjuvant and has obvious therapeutic effect on transplanted TC-1 cell tumor of mouse.

The invention proposes PD-L1 antibody secretion anti-mesothelin CAR-T cell tumor immunotherapy. CAR-T cells co-express an anti-PD-L1 fusion antibody, non-functional EGFR and a chimeric antigen receptor, wherein the anti-PD-L1 fusion antibody is formed by linking an anti-PD-L1 single-chain antibody to an IgG1Fc fragment containing amino acid mutation. The transgenic lymphocyte secretes the anti-PD-L1 single-chain antibody and an IgG Fc fusion antibody, and has the characteristics of resisting tumor cell-mediated immunosuppression, significantly enhanced killing ability to tumor cells, especially a significant targeted killing effect on tumors highly expressing mesothelin and PD-L1 molecules, and high safety.

The invention relates to a tumor targeting polypeptide and a preparation method thereof. The amino acid sequential structure of the polypeptide of the invention is CFPVPGHDLVC. The preparation method comprises the following steps: co-culturing a pC89 phage peptide library for expressing 108 protein polypeptides with different sequences and human breast cancer cell strain MDA-MB-231 repeatedly formany times; screening phages which express specific polypeptides and can penetrate a cell membrane and enter cytoplasm and / or nucleus, amplifying the phages in vitro and carrying out DNA sequencing, and deducing exogenous amino acid sequences inserted on the phages; co-culturing the screened specific polypeptide phages, other human tumor cells and normal cells in vitro, and detecting the specificity of cell tumor of the polypeptide phages; and according to the polypeptide sequences and the detecting result of the cell specificity, artificially synthesizing the tumor targeting polypeptide. Theinvention has potential clinical application values for specific vectors of breast cancer targeting gene therapy, and also provides powerful technical support for screening polypeptides with affinityand specificity of other types of malignant tumor cell strains in the future. In addition, the polypeptide of the invention contains only 9-11 amino acid residues, can be synthesized easily, and has relatively small spatial position change, easy quality control of the polypeptide and convenient use.

The invention provides a CLL1 and CD33 double-target chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane domain and a signal transduction domain, and the antigen binding domain comprises an anti-CLL1 single-chain antibody and an anti-CD33 single-chain antibody. According to the constructed CAR molecule simultaneously targeting CLL1 and CD33, the effect of comprehensively targeting acute myelogenous leukemia cells is achieved, the CAR-T cells for expressing CLL1 and CD33 double-target CAR are remarkable in tumor removal effect, the antigen escape phenomenon is avoided, and the CAR molecule has important significance in the field of tumor treatment.

The invention relates to HPK1-targeted gRNA and an editing method aiming at an HPK1 gene. According to HPK1gRNA and the editing method of the HPK1 gene, the HPK1 gene of the T cell can be knocked out,the killing activity of the T cell can be improved, the Th1 cell factor level of a peripheral blood monouclear cell can be increased; and by knocking out the HPK1 gene of the T cell, the expression of PD-1 and TIM3 on the surface of the T cell can be decreased, and the failure of the T cell can be inhibited. Therefore, HPK1-targeted gRNA can be used for preparing tumor treatment drug and can be particularly applied to targeting therapy methods (CRA-T, CAR-NK, CAR-NKT and CAR-gammadelta) for chimeric antigen receptor cell tumors.

The invention relates to preparation of low molecular weight polysaccharides of Porphyra yezoensis and application of the low molecular weight polysaccharides of Porphyra yezoensis in resisting humancervical cancer cell tumors, and belongs to the field of biochemistry. The preparation is technically characterized in that macromolecular polysaccharides of Porphyra yezoensis are extracted by hot water boiling process first and are degraded into small molecular polysaccharides by gamma-ray radiation; the small molecular polysaccharides are mainly applied to resisting human cervical cancer cell tumors. The preparation method provided herein employs simple extraction process and is suitable for industrial production; the polysaccharides of Porphyra yezoensis prepared via the preparation methodhave a good anti-tumor function, are free of cell toxicity and are good in safety and reliability.

The invention provides a novel preparation for mobilization of bone marrow hematopoietic stem cells. The novel preparation comprises DEO, and the dosage range of DFO is 1-15mg / kg. Preferably, DFO and BOP are combined for use. The novel preparation has the following two obvious advantages: 1, the mobilization period is short, and only one or more hours are needed for effectively collecting bone marrow stem cells from a supplier; 2, compared with a traditional method, the method has no side effect, and adverse reactions like hematological cell tumors cannot be induced.

A method of preparing the dendritic cell tumor vaccine includes steps as follows. A tumor specimen is primarily isolated and cultured to obtain a plurality of tumor cells. Cancer stem cells having a specific cell surface marker are sorted from the tumor cells. The cancer stem cells are irradiated with a radiation. A plurality of dendritic cells are provided. The dendritic cells and the cancer stem cells irradiated with the radiation are co-cultured for activating the dendritic cells into cancer-stem-cell-antigen-presenting dendritic cells to obtain the dendritic cell tumor vaccine. The dendritic cell tumor vaccine is a mixture of the cancer-stem-cell-antigen-presenting dendritic cells and the cancer stem cells.